Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial.

Lamarca A, Palmer DH, Wasan HS, Ross PJ, Ma YT, Arora A, Falk S, Gillmore R, Wadsley J, Patel K, Anthoney A, Maraveyas A, Iveson T, Waters JS, Hobbs C, Barber S, Ryder WD, Ramage J, Davies LM, Bridgewater JA, Valle JW, Advanced Biliary Cancer Working Group. · 2021

Read Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial. by Lamarca A, Palmer DH, Wasan HS, Ross PJ, Ma YT, Arora A, Falk S, Gillmore R, Wadsley J, Patel K, Anthoney A, Maraveyas A, Iveson T, Waters JS, Hobbs C, Barber S, Ryder WD, Ramage J, Davies LM, Bridgewater JA, Valle JW, Advanced Biliary Cancer Working Group. (2021) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc8082275.txt.

Description

Lamarca and co-authors test second-line FOLFOX chemotherapy against symptom control alone in advanced biliary tract cancer. The ABC-06 trial was a phase 3 study run at 20 UK sites. Patients had progressed after first-line cisplatin and gemcitabine. A total of 162 patients were randomized evenly. One arm got active symptom control plus FOLFOX. The other got symptom control alone.

Overall survival ran longer on the chemotherapy arm. Median survival reached 6.2 months on FOLFOX against 5.3 months on symptom control alone in the final analysis. The adjusted hazard ratio was 0.69 in favor of chemotherapy across the trial. At 12 months, 25.9% of the FOLFOX group were alive against 11.4% of the control group in the same count. Side effects were heavier with the drugs, as expected. The authors call FOLFOX a valid second-line standard.

Catalog record

CREATORLamarca A, Palmer DH, Wasan HS, Ross PJ, Ma YT, Arora A, Falk S, Gillmore R, Wadsley J, Patel K, Anthoney A, Maraveyas A, Iveson T, Waters JS, Hobbs C, Barber S, Ryder WD, Ramage J, Davies LM, Bridgewater JA, Valle JW, Advanced Biliary Cancer Working Group.
YEAR2021
COLLECTIONPAPERS
FORMATTXT
FILE SIZE60 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC8082275

Browse the full library · About the Tower of Babel